Bioscience

TGen becomes center of excellence for Horizon Discovery

February 2, 2010

By Flinn Foundation

[Source: TGen] – The Translational Genomics Research Institute (TGen) and Horizon Discovery today announced plans to develop human disease models for use in TGen’s cancer research.

A research-collaboration and sub-licensing agreement will allow TGen investigators to use Horizon’s GENESIS™ and X-MAN™ technologies to accelerate the search for new drug targets, biomarkers and anti-cancer agents, which could provide patients with more effective treatments.

Dr. Daniel Von Hoff, TGen’s Physician-In-Chief and senior investigator will head the effort at TGen. Dr. Von Hoff is a leading advocate of developing precision cancer therapies. Dr. Von Hoff also is a leader in clinical trial design for agents that are based on an understanding of the cancer genes in patients’ tumors.

For more information: The Translational Genomics Research Institute (TGen) becomes center of excellence for Horizon Discovery’s GENESIS and X-MAN technology